This document appears to be about PD-L1 training that took place internationally in 2016. It likely provided instruction on the PD-L1 biomarker and its role in cancer immunotherapy. The training was probably attended by medical professionals from different countries to educate them on recent developments regarding PD-L1 and help advance cancer treatment worldwide.